N/A N=1,087 Mobile Messaging for Improved Nutrition
Diet, Healthy · Anemia
Primary: Number of Children Who Consume a Minimum Acceptable Diet — 67; 92; 138; 191 Participants — p=0.145
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16 — -62.17; -85.39; -92.93; 4.64 percentage change — p=< 0.0001
Phase 4 N=3,591 Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Covid19
Primary: 21 Day Organ Support (Respiratory or Vasopressor) Free Days — 22; 22; 17; 17 days — p=.6778
Phase 2 N=34 A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
Neovascular Age-related Macular Degeneration · Macular Edema · Retinal Vein Occlusion
Primary: Percentage of Successful Task Completions — 100; 100; 100; 100 Percentage of successful task completion
N/A N=3,504 Consumer Perceptions of Cannabidiol (CBD) Health Claims
Perceptions
Primary: Perceived Claim Scores — 2.96; 2.81; 2.71; 2.03 score on a scale
Phase 3 N=32 Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Patients Who Achieved Clinical Response — 57; 35 percentage of patients — p=0.05
N/A N=82 Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women
Urge Incontinence
Primary: Change in Average Number of Urinary Incontinence Episodes Per Day — 69.6; 66.1 percentage change — p=<0.0001
Phase 4 N=32 Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Tenosynovial Giant Cell Tumor
Primary: Number of Treatment-Free Participants at 12 Months In The Treatment-free/Re-treatment Cohort — 8 Participants
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 2 N=144 A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
Dermatitis, Atopic · Pruritus
Primary: Daily Peak Pruritus Numerical Rating Scale (NRS) — -45.6; -55.8; -48.3; -49.9 percent change — p=0.5483
Phase 1 N=12 A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males
No Condition
Primary: Plasma PK Concentrations and Parameters of Ketoprofen (Part A): Area Under the Concentration-time Curve (AUC) From Zero to the Last Quantifiable Concentrations (AUC0-t)…
N/A N=109 Flatbush FHC Proactive Colorectal Cancer Screening and Navigation
Colorectal Cancer
Primary: Number of Participants Who Complete Initial Fecal Immunochemical Test (FIT) at 6 Months — 7; 0 Participants
N/A N=5 Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE)
Colonoscopy
Primary: MFE Navigation to the Cecum From the Rectum in Less Than 40 Minutes — 0 Participants
N/A N=21 The Effects of Contact Lenses With UV/HEV-Filter on Visual Function
Visual Acuity
Primary: Visual Range at Phase 1 — 3.232; 3.049; 3.287; 3.167 log relative energy level
N/A N=51 Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
Hematologic Neoplasms
Primary: Content Validity of Best-Worst Scaling (BWS) Survey — 10; 0 Participants